125 / 164
255
24-hour acute glucose fluctuations. J Diabetes Complications
2010;24: 79-83.
72. Guerci B, Monnier L, Serusclat P, et al. Continuous glucose
profiles with vildagliptin versus sitagliptin in addon to
metformin: results from the randomized Optima study.
Diabetes Metab 2012;38: 359-66.
73. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy
in type 2 diabetes: Systematic review and meta-analysis. JAMA
2007; 298:194-206.
74. Wu, D.; Li, L.; Liu, C. Efficacy and safety of dipeptidyl peptidase-
4 inhibitors and metformin as initial combination therapy and
as monotherapy in patients with type 2 diabetes mellitus: a
metaanalysis Diabetes Obes. Metab., 2014, 16, 30-37.
75. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas
A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2
diabetes mellitus in the clinical setting: systematic review and
meta-analysis. BMJ. 2012; 344:e1369.
76. Scheen A.J. DPP-4 inhibitors in the management of type 2
diabetes: A critical review of head-to-head trials. Diabetes &
Métabolism 2012; 38: 89-101.
77. Filozof C, Gautier JF. A comparison of efficacy and safety of
vildagliptin and gliclazide in combination with metformin in
patients with Type 2 diabetes inadequately controlled with
metformin alone: a 52-week, randomized study. Diabet Med
2010; 27: 318-326.
78. Derosa G, Cicero AF, Franzetti IG, et al. A randomized, double-
blind, comparative therapy evaluating sitagliptin versus
glibenclamide in type 2 diabetes patients already treated with
pioglitazone and metformin: a 3-year study. Diabetes Technol
Ther 2013;15: 214-222.
79. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and
safety of linagliptin compared with glimepiride in patients
with type 2 diabetes inadequately controlled on metformin:
a randomised, double-blind, noninferiority trial. Lancet
2012;380: 475-483.
80. Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W. Head-to-
head comparison of dipeptidyl peptidase-IV inhibitors and
sulfonylureas - a meta-analysis from randomized clinical
trials. Diabetes Metab Res Rev. 2014; 30:241-256.
81. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of
the glycemia reduction approaches in diabetes: a comparative
effectiveness study (GRADE). Diabetes Care 2013; 36:2254-
2261.
82. Downes M J, Bettington E, Gunton J E, Turkstra E. Triple therapy
in type 2 diabetes; a systematic review and network meta-
analysis. Peer J. 2015; 3: e1461. doi: 10.7717/peerj.1461.
83. Karagiannis T, Boura P, and Tsapas A. Safety of dipeptidyl
peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf.
2014; 5: 138–146.
84. FDA Drug Safety Communication: FDA warns that DPP-4
inhibitors for type 2 diabetes may cause severe joint pain. http://
www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf
85. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes
mellitus. N Engl J Med 2013; 369: 1317–1326.
86. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute
coronary syndrome in patients with type 2 diabetes. N Engl J
Med 2013;369: 1327-1335.
87. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin
on cardiovascular outcomes in type 2 diabetes. N Engl J Med
2015; 373: 232-242.
88. Koska J, Sands M, Burciu C, Reaven P. Cardiovascular effects
of dipeptidyl peptidase- 4 inhibitors in patients with type 2
diabetes. Diabetes and Vascular Disease Research May 2015;
12: 154-163.
89. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin,
and diabetes mellitus: observations from the SAVOR-TIMI 53
randomized trial. Circulation 2014;130: 1579-1588.
90. Zannad F, Cannon CP, Cushman WC, et al. Heart failure
and mortality outcomes in patients with type 2 diabetes
taking alogliptin versus placebo in EXAMINE: a multicentre,
randomised, double-blind trial. Lancet 2015 385: 2067-
2076.
91. Davis TM. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics,
efficacy, tolerability and safety in renal impairment. Diabetes
Obes Metab 2014; 16: 891-899.
92. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic
impairment on the pharmacokinetics of saxagliptin. Clin
Pharmacokinet 2011;50: 253-65.
93. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics
of linagliptin in subjects with hepatic impairment. Br J Clin
Pharmacol 2012;74: 75-85.
94. Doucet J, Chacra A, Maheux P, Lu J, Harris S , Rosenstock J.
Efficacy and safety of saxagliptin in older patients with type 2
diabetes mellitus. Current Med. Research &Opinion 2011; 27:
863–869.
95. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical
experience with vildagliptin in the management of type 2
diabetes in a patient population ≥ 75 years: a pooled analysis
from a database of clinical trials. Diabetes Obes Metab. 2011;
13:55–64.
96. Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle
HJ. Linagliptin for patients aged 70 years or older with type 2
diabetes inadequately controlled with common antidiabetes
treatments: a randomised, double-blind, placebo-controlled
trial. Lancet. 2013; 382:1413–1423.
97. Shankar RR, Xu L, Golm G, O’Neill E, Goldstein B, Kaufman K,
Engel S. A Comparison of Glycaemic Effects of Sitagliptin and
Sulfonylureas in Elderly Patients With Type 2 Diabetes Mellitus.
Int J Clin Pract. 2015; 69:626-631.
98. Avogaro A, Dardano A, S. de Kreutzenberg V, Del Prato
S. Dipeptidyl peptidase-4 inhibitors can minimize the
hypoglycaemic burden and enhance safety in elderly people
with diabetes. Diabetes, Obesity and Metabolism 2015; 17:
107–115.
99. Leiter L A, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar P
et al. Efficacy and Safety of Saxagliptin in Older Participants in
the SAVOR-TIMI 53 Trial. Diabetes Care 2015; 38: 1145-1153
[Nuevos fármacos en Diabetes Mellitus - Dra. Carmen Gloria Aylwin H.]